Jefferies puts Endo on hold

Endo Pharmaceuticals Holdings, Inc. was given a hold rating by Jefferies & Co., Inc. analyst David Windley as growth in the Opana franchise over the past two to three weeks sparked a rally in the stock. But, Windley believes achieving management's 2006 forecast of $20 million to $30 million is difficult without meaningful channel stocking on top of total prescription growth. Jefferies lowered its third-quarter Lidoderm sales forecast by 6.5% to $130 million. Shares of the Chadds Ford, Pa.-based pharmaceutical company were down 76 cents, or 2.29%, at $32.37. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.